{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-122830","form_type":"8-K","ticker":"APVO","cik":"0001671584","company_name":"Aptevo Therapeutics Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.176746+00:00","generated_at":"2026-05-30T03:37:33.788668+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aptevo Q3 net loss $5.1M; cash $7.8M; initiates RAINIER trial for AML","bullets":["Net loss of $5.1M ($0.48 per share) in Q3 2024 vs $6.3M ($22.16) in Q3 2023.","Cash and cash equivalents $7.8M as of Sept 30, 2024, down from $16.9M at Dec 31, 2023.","Initiated Phase 1b/2 RAINIER trial for mipletamig in frontline AML based on positive dose escalation data.","ALG.APV-527 Phase 1 data: 60% of evaluable patients (9/15) achieved stable disease as monotherapy.","Raised $5.75M in two financings during the quarter."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-122830","json":"https://secwatch.observer/filing/0000950170-24-122830.json","markdown":"https://secwatch.observer/filing/0000950170-24-122830.md","text":"https://secwatch.observer/filing/0000950170-24-122830.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671584/000095017024122830/0000950170-24-122830-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671584/000095017024122830/apvo-20241107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:37:33.788668+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}